Human papillomavirus vaccines: Current status and perspectives

Biotecnologia Aplicada

Volumn 25, Issue 1, 2008, Pages 1-6

  Granadillo, Milaid ^a   Torréns, Isis ^a  

^a CENTER FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Cuba)

Author keywords

Cervical cancer; HPV; Vaccines

Indexed keywords

ANTIVIRUS AGENT; DENDRITIC CELL VACCINE; DNA VACCINE; HEAT SHOCK PROTEIN 70; PEPTIDE VACCINE; PROTEIN E7; RECOMBINANT PROTEIN; VIRUS VECTOR; WART VIRUS VACCINE;

CLINICAL TRIAL; DRUG EFFICACY; DRUG POTENCY; DRUG POTENTIATION; DRUG SAFETY; DRUG TARGETING; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; NONHUMAN; REVIEW; UTERINE CERVIX CANCER; VIRUS CAPSID; VIRUS INFECTION; VIRUS LIKE AGENT;

HUMAN PAPILLOMAVIRUS; MIRIDAE;

EID: 57149097653     PISSN: 08644551     EISSN: 10272852     Source Type: Journal    
DOI: None     Document Type: Review

References (78)

1. Parkin DM. World burden of infection-associated cancers. 22nd International Papillomavirus Conference, April 30 - May 6, Vancouver, Canada; 2005. p. 10.
2. Muñoz N, Bosch FX, Castellsagué X, Díaz M, de Sanjose S, Hammouda D et al. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer 2004,111:278-85.
3. Ramírez JE, Ramos DM, Clayton L, Kanowitz S, Moscicki AB. Genital human papillomavirus infections: knowledge, perception of risk, and actual risk in a non-clinic population of young women. J Women's Health 1997;6:113-21.
4. Yacobi E, Tennant C, Ferrante J, Pal N, Roetzheim R. University students' knowledge and awareness of HPV Prev Med 1999;28:535-41.
5. Dell DL, Chen H, Ahmad F, Stewart DE. Knowledge about human papillomavirus among adolescents. Obstet Gynecol 2000;96:653-56.
6. Lowy DR, Howley PH. Papillomaviruses. In Fields virology. DM Knipe and PH Howley, editors. Lippincott, Williams & Wilkins. Philadelphia, Pennsylvania, USA; 2001.
7. Zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2002;2:342-50.
8. Bosch FX, Schiffman M, Solomon D, editors. Future directions in epidemiologic and preventive research on human papillomaviruses and cancer. J Natl Cancer Inst Monogr 2003.
9. Schiffman M, Kjaer SK. Chapter 2: natural history of anogenital human papillomavirus infection and neoplasia. J Natl Cancer Inst Monogr 2003. p.14-9.
10. Pitts M, Clarke T. Human papillomavirus infections and risks of cervical cancer: what do women know? Health Educ Res 2002;17:706-14.
11. Ho GY, Bierman R, Beardsley L, Chang CJ, Burk RD. Natural history of cervicovaginal papillomavirus infection in young women. New Engl J Med 1998;338:423-28.
12. Kahn JA, Rosenthal SL, Succop PA, Ho GY, Burk RD. Mediators of the association between age of first sexual intercourse and subsequent human papillomavirus infection. Pediatrics 2002;109:E5.
13. Snijders PJ, Steenbergen RD, Heideman DA, Meijer CJ. HPV-mediated cervical carcinogenesis: concepts and clinical implications. J Pathol 2006;208:152-64.
14. World Health Organization. Initiative for vaccine research. Human papillomavirus. 2006. Geneva, Switzerland, World Health Organization, http://www.who.int/vaccineresearch/diseasesviral_cancers/en/index3.html. Accessed 6/29/06.
15. Kirnbauer R, Booy F, Cheng N, Lowy DR, Schiller JT Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc Natl Acad Sci USA 1992;89:12180-4.
16. Zinkernagel RM. On natural and artificial vaccinations. Annu Rev Immunol 2003;21:515-46.
17. JB, Schneerson R, Szu SC. Hypothesis: serum IgG antibody is sufficient to confer protection against infectious diseases by inactivating the inoculum. J Infect Dis 1995;171:1387-98.
18. Hagensee ME, Yaegashi N, Galloway DA. Self-assembly of human papillomavirus type 1 capsids by expression of the L1 protein alone or by coexpression of the L1 and L2 capsid proteins. J Virol 1993;67:315-22.
19. Rose RC, Reichman RC, Bonnez W. Human papillomavirus HPV type 11 recombinant virus-like particles induce the formation of neutralizing antibodies and detect HPV-specific antibodies in human sera. J Gen Virol 1994;75:2075-79.
20. Breitburd F, Kirnbauer R, Hubbert NL, Nonnenmacher B, Trin-Dinh-Desmarquet C, Orth G et al. Immunization with virus like particles from cottontail rabbit papillomavirus CRPV can protect against experimental CRPV infection. J Virol 1995;69:3959-63.
21. Muñoz N, Bosch FX, de Sanjosé S, Herrero R, Castellsagué X, Shah KV et al. International Agency for Research on Cancer Multicenter Cervical Cancer Study Group. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003;348:518-27.
22. Villa LL, Costa RL, Petta CA, Andrade RR Ault KA, Giuliano AR et al. Prophylac-tic quadrivalent human papillomavirus types 6, 11, 16, and 18 L1 virus-like particle vaccine in young women: a randomized double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005;6:271-8.
23. Harper DM, Franco EL, Wheeler C, Ferris DG, Jenkins D, Schuind A et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 2004;364:1757-65.
24. FDA licenses new vaccine for prevention of cervical cancer and other diseases in females caused by human papillomavirus. Available from: http://www.fda.gov/bbs/topics/NEWS/2006/NEW01385.htm
25. National Cancer Institute: Cancer Vaccine Fact Sheet. Available at: http://www.nci.nih.gov/cancertopics/factsheet/cancervaccine
26. Olsson SE, Villa LL, Costa RL, Petta CA, Andrade RR Malm C et al. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine. Vaccine 2007;25:4931-9.
27. Harper DM, Franco EL, Wheeler CM, Moscicki AB, Romanowski B, Roteli-Martins CM et al. Sustained efficacy up to 4.5 years of a bivalent L1virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 2006;367:1247-55.
28. Embers ME, Budgeon LR, Pickel M, Christensen ND. Protective immunity to rabbit oral and cutaneous papillomaviruses by immunization with short peptides of L2, the minor capsid protein. J Virol 2002;76:9798-805.
29. Pastrana DV, Gambhira R, Buck CB, Pang YY, Thompson CD, Culp TD et al. Cross-neutralization of cutaneous and mucosal Papillomavirus types with antisera to the amino terminus of L2. Virology 2005;337:365-72.
30. Alphs HH, Gambhira R, Karanam B, Roberts JN, Jagu S, Schiller JT et al. Protection against heterologous human papillomavirus challenge by a synthetic lipopeptide vaccine containing a broadly cross-neutralizing epitope of L2. Proc Natl Acad Sci USA 2008;105:5850-5.
31. Taira AV, Neukermans CR Sanders GD. Evaluating human papillomavirus vaccination programs. Emerg Infect Dis 2004;10:1915-23.
32. Schiller JT, Lowy DR. Papilloma virus-like particles and HPV vaccine development. Semin Cancer Biol 1996;7:373-82.
33. Littler E, Oberg B. Achievements and challenges in antiviral drug discovery. Antivir Chem Chemother 2005;16:155-68.
34. Ahn WS, Bae SM, Kim TY, Kim TG, Lee JM, Namkoong SE et al. Atherapy modality using recombinant IL-12 adenovirus plus E7 protein in a human papillomavirus 16 E6/E7-associated cervical cancer animal model. Hum Gene Ther 2003;14:1389-99.
35. Borysiewicz LK, Fiander A, Nimako M, Man S, Wilkinson GW, Westmoreland D et al. A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer. Lancet 1996;347:1523-27.
36. Lamikanra A, Pan ZK, Isaacs SN, Wu TC, Paterson Y. Regression of established human papillomavirus type 16 HPV-16 immortalized tumors in vivo by vaccinia viruses expressing different forms of HPV-16 E7 correlates with enhanced CD84- T-cell responses that home to the tumor site. J Virol 2001;75:9654-64.
37. Kaufmann AM, Stern PL, Rankin EM, Sommer H, Nuessler V, Schneider A et al. Safety and immunogenicity of TA-HPV, a recombinant vaccinia virus expressing modified human papillomavirus HPV-16 and HPV-18 E6 and E7 genes, in women with progressive cervical cancer. Clin Cancer Res 2002;8:3676-85.
38. Davidson EJ, Boswell CM, Sehr P, Pawlita M, Tomlinson AE, McVey RJ et al. Immunological and clinical responses in women with vulval intraepithelial neoplasia vaccinated with a vaccinia virus encoding human papillomavirus 16/18 oncoproteins. Cancer Res 2003;63:6032-41.
39. He Z, Wlazlo AP, Kowalczyk DW, Cheng J, Xiang ZQ, Giles-Davis W et al. Viral recombinant vaccines to the E6 and E7 antigens of HPV-16. Virology 2000;270:146-61.
40. Gómez-Gutierrez JG, Elpek KG, Montes de Oca-Luna R, Shirwan H, Sam Zhou H, McMasters KM. Vaccination with an adenoviral vector expressing calreticulin-human papillomavirus 16 E7 fusion protein eradicates E7 expressing established tumors in mice. Cancer Immunol Immunother 2007;56:997-1007.
41. Liu DW, Tsao YP, Kung JT, Ding YA, Sytwu HK, Xiao X et al. Recombinant adeno-associated virus expressing human papillomavirus type 16 E7 peptide DNA fused with heat shock protein DNA as a potential vaccine for cervical cancer. J Virol 2000;74:2888-94.
42. Daemon T, Riezebos-Brilman A, Regts J, Dontje B, van der Zee A, Wilschut J. Superior therapeutic efficacy of alpha-virus-mediated immunization against human papilloma virus type 16 antigens in a murine tumour model: effects of the route of immunization. Antivir Ther 2004;9:733-42.
43. Riezebos-Brilman A, Regts J, Freyschmidt EJ, Dontje B, Wilschut J, Daemen T. Induction of human papilloma virus E6/E7-specific cytotoxic T-lymphocyte activity in immune-tolerant, E6/E7-transgenic mice. Gene Ther 2005;12:1410-4.
44. Nishimoto KP, Laust AK, Wang K, Kamrud KI, Hubby B, Smith JF et al. Restricted and selective tropism of a Venezuelan equine encephalitis virus-derived replicon vector for human dendritic cells. Viral Immunol 2007;20:88-104.
45. Krul MR, Tijhaar EJ, Kleijne JA, Van Loon AM, Nievers MG, Schipper H et al. Induction of an antibody response in mice against human papillomavirus HPV type 16 after immunization with HPV recombinant Salmonella strains. Cancer Immunol Immunother 1996;43:44-8.
46. Jabbar IA, Fernando GJ, Saunders N, Aldovini A, Young R, Malcolm K et al. Immune responses induced by BCG recombinant for human papillomavirus L1 and E7 proteins. Vaccine 2000;18:2444-53.
47. Gunn GR, Zubair A, Peters C, Pan ZK, Wu TC, Paterson Y. Two Listeria monocytogenes vaccine vectors that express different molecular forms of human papilloma virus-16 HPV-16 E7 induce qualitatively different T cell immunity that correlates with their ability to induce re-gression of established tumors immortalized by HPV-16. J Immunol 2001;167:6471-79.
48. Bermúdez-Humarán LG, Cortes-Pérez NG, Lefèvre F, Guimarães V, Rabot S, Alcocer-Gonzalez JM et al. A novel mucosal vaccine based on live Lactococci expressing E7 antigen and IL-12 induces systemic and mucosal immune responses and protects mice against human papillomavirus type 16-induced tumors. J Immunol 2005;175:7297-302.
49. Souders NC, Sewell DA, Pan ZK, Hussain SF, Rodriguez A, Wallecha A et al. Listeria-based vaccines can overcome tolerance by expanding low avidity CD8+ T cells capable of eradicating a solid tumor in a transgenic mouse model of cancer. Cancer Immun 2007;7:2.
50. Steller MA, Gurski KJ, Murakami M, Daniel RW, Shah KV, Cells E et al. Cell-mediated immunological responses in cervical and vaginal cancer patients immunized with a lipidated epitope of human papillomavirus type 16 E7. Clin Cancer Res 1998;4:2103-09.
51. Muderspach L, Wilczynski S, Roman L, Bade L, Felix J, Small LA et al. A phase I trial of a human papillomavirus HPV peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive. Clin Cancer Res 2000;6:3406-16.
52. Zwaveling S, Ferreira Mota SC, Nou-ta J, Johnson M, Lipford GB, Offringa R et al. Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides. J Immunol 2002;169:350-8.
53. Cui Z, Qiu F. Synthetic double-stranded RNA polyl:C as a potent peptide vaccine adjuvant: therapeutic activity against human cervical cancer in a rodent model. Cancer Immunol Immunother 2005;54:1180-90.
54. Mesa C, de Leon J, Rigley K, Fernández LE. Very small size proteoliposomes derived from Neisseria meningitidis: an effective adjuvant for Th1 induction and dendritic cell activation. Vaccine 2004;22:3045-52.
55. Torrens I, Mendoza O, Batte A, Reyes O, Fernández LE, Mesa C et al. Immunotherapy with CTL peptide and VSSP eradicated established human papillomavirus HPV type 16 E7-expressing tumors. Vaccine 2005;23:5768-74.
56. Daftarian P, Mansour M, Benoit AC, Pohajdak B, Hoskin DW, Brown RG et al. Eradication of established HPV 16-expressing tumors by a single administration of a vaccine composed of a liposome-encapsulated CTL-T helper fusion peptide in a water-in-oil emulsion. Vaccine 2006;24:5235-44.
57. Daftarian PM, Mansour M, Pohajdak B, Fuentes-Ortega A, Korets-Smith E, Macdonald L et al. Rejection of large HPV-16 expressing tumors in aged mice by a single immunization of VacciMax encapsulated CTL/T helper peptides. J Transl Med 2007;5:26.
58. Vambutas A, DeVoti J, Nouri M, Drijfhout JW, Lipford GB, Bonagura VR et al. Therapeutic vaccination with papillomavirus E6 and E7 long peptides results in the control of both established virus-induced lesions and latently infected sites in a pre-clinical cottontail rabbit papillomavirus model. Vaccine 2005;23:5271-80.
59. Kenter GG, Welters MJ, Valentijn AR, Lowik MJ, Berends-van der Meer DM, Vloon AP et al. Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high risk HPV16 in end stage cervical cancer patients shows low toxicity and robust immunogenicity. Clin Cancer Res 2008;14:169-77.
60. Welters MJ, Kenter GG, Piersma SJ, Vloon AP, Löwik MJ, Berends-van der Meer DM et al. Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine. Clin Cancer Res 2008;14:178-87.
61. Fernando GJ, Murray B, Zhou J, Frazer IH. Expression, purification and immunological characterization of the transforming protein E7, from cervical cancer-associated human papillomavirus type 16. Clin Exp Immunol 1999;115:397-403.
62. Kim TY, Myoung HJ, Kim JH, Moon IS, Kim TG, Ahn WS et al. Both E7 and CpG-oligodeoxynucleotide are required for protective immunity against challenge with human papillomavirus 16 E6/E7 immortalized tumor cells: involvement of CD4+ and CD8+ Tcells in protection. Cancer Res 2002;62:7234-40.
63. Chu NR, Wu HB, Wu TC, Boux LJ, Mizzen LA, Siegel MI. Immunotherapy of a human papillomavirus HPV type 16 E7-expressing tumour by administration of fusion protein comprising Mycobacterium bovis bacilli Calmette-Guerin BCG hsp65 and HPV16 E7. Clin Exp Immunol 2000;121:216-25.
64. Einstein MH, Kadish AS, Burk RD. HSP-based immunotherapy HspE7 for treatment of CIN 3. Gynecol Oncol 2005;96:912a-913a.
65. Palefsky JM, Berry JM, Jay N, Krogstad M, Da Costa M, Darragh TM et al. A trial of SGN-00101 HspE7 to treat high-grade anal intraepithelial neoplasia in HIV-positive individuals. AIDS 2006;20:1151-5.
66. Roman LD, Wilczynski S, Muderspach LI, Burnett AF, O'Meara A, Brinkman JA,et al. A phase II study of Hsp-7 SGN-00101 in women with high-grade cervical intraepithelial neoplasia. Gynecol Oncol 2007;106:558-66.
67. Einstein MH, Kadish AS, Burk RD, Kim MY, Wadler S, Streicher H et al. Heat shock fusion protein-based immunotherapy for treatment of cervical intraepithelial neoplasia III. Gynecol Oncol 2007;106:453-60.
68. de Jong A, O'Neill T, Khan AY, Kwappenberg KM, Chisholm SE, Whittle NR et al. Enhancement of human papillomavirus HPV type 16 E6 and E7-specific T-cell immunity in healthy volunteers through vaccination with TA-CIN, an HPV16 L2E7E6 fusion protein vaccine. Vaccine 2002;20:3456-64.
69. Lacey CJ, Thompson HS, Monteiro EF, O'Neill T, Davies ML, Holding FP et al. Phasella safety and immunogenicity of a therapeutic vaccine, TA-GW, in persons with genital warts. J Infect Dis 1999;179:612-8.
70. Ji H, Wang TL, Chen CH, Pai SI, Hung CF, Lin KY et al. Targeting human papillomavirus type 16 E7 to the endosomal/lysosomal compartment enhances the antitumor immunity of DNA vaccines against murine human papillomavirus type 16 E7-expressing tumors. Hum Gene Ther 1999;10:2727-40.
71. Kim TW, Hung CF, Boyd D, Juang J, He L, Kim JW et al. Enhancing DNA vaccine potency by coadministration of DNA encoding antiapoptotic proteins. J Clin Invest 2003;112:109-17.
72. Hsu KF, Hung CF, Cheng WF, He L, Slater LA, Ling M et al. Enhancement of suicidal DNA vaccine potency by linking Mycobacterium tuberculosis heat shock protein 70 to an antigen. Gene Ther 2001;8:376-83.
73. Li Y, Subjeck J, Yang G, Repasky E, Wang XY. Generation of anti-tumor immunity using mammalian heat shock protein 70 DNA vaccines for cancer immunotherapy. Vaccine 2006;24:5360-70.
74. Garcia F, Petry KU, Muderspach L, Gold MA, Braly P, Crum CP et al. ZYC101a for treatment of highgrade cervical intraepithelial neoplasia: a randomized controlled trial. Obstet Gynecol 2004;103:317-26.
75. Ray NB, Ewalt LC, Lodmell DL. Nanogram quantities of plasmid DNA encoding the rabies virus glycoprotein protect mice against lethal rabies virus infection. Vaccine 1997;15:892-5.
76. Trimble C, Lin CT, Hung CF, Pai S, Juang J, He L et al. Comparison of the CD8+ T cell responses and antitumor effects generated by DNA vaccine administered through gene gun, biojector, and syringe. Vaccine 2003;21:4036-42.
77. Santin AD, Hermonat PL, Ravaggi A, Chiriva-Internati M, Zhan D, Pecorelli S et al. Induction of human papillomavirus-specific CD4+ and CD8+ lymphocytes by E7-pulsed autologous dendritic cells in patients with human papillomavirus type 16- and 18-positive cervical cancer. J Virol 1999;73:5402-10.
78. Ferrara A, Nonn M, Sehr P, Schreckenberger C, Pawlita M, Durst M et al. Dendritic cell-based tumor vaccine for cervical cancer II: results of a clinical pilot study in 15 individual patients. J Cancer Res Clin Oncol 2003;129:521-30.